Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
Winter MP, Grove EL, De Caterina R, Gorog DA, Ahrens I, Geisler T, Gurbel PA, Tantry U, Navarese EP, Siller-Matula JM.
Winter MP, et al.
Eur Heart J Cardiovasc Pharmacother. 2017 Oct 1;3(4):221-234. doi: 10.1093/ehjcvp/pvw044.
Eur Heart J Cardiovasc Pharmacother. 2017.
PMID: 28204303
Review.
Antiplatelet therapy with P2Y12-receptor inhibitors has become the cornerstone of medical treatment in patients with acute coronary syndrome treated with percutaneous coronary intervention (PCI). With over 100 million prescriptions filled since its approval, clopidogrel is …
Antiplatelet therapy with P2Y12-receptor inhibitors has become the cornerstone of medical treatment in patients with acute coronary syndrome …